Bard Fluency Plus Endovascular Stent Graft
Bard Peripheral Vascular, Inc. · Decision date Jun 10, 2026
What did the FDA decide?
FDA records P130029/S014 as a supplement to PMA P130029, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jun 10, 2026.
FDA approval order statement
changes to the packaging supplier's adhesive coating
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Jun 10, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P130029/S014
- Regulatory pathway
- PMA supplement
- Applicant
- Bard Peripheral Vascular, Inc.
- Product code
- PFV
- Decision code
- OK30
- Decision date
- Jun 10, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, endovascular graft, arteriovenous (AV) dialysis access circuit stenosis treatment.
- Applicant
- Bard Peripheral Vascular, Inc.
- Product code
- PFV
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P130029/S013 · Related supplement
FLUENCY PLUS ENDOVASCULAR STENT GRAFT
P130029/S014 received
Application receipt date recorded by FDA.
P130029/S014 · FDA decision
30-Day Notice
P130029/S015 · Related supplement
Fluency Plus Endovascular Stent Graft
Timeline entries are records held by MedtechLedger for P130029. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P130029
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
FLUENCY PLUS ENDOVASCULAR STENT GRAFTP130029/S013 | Bard Peripheral Vascular, Inc. | PMA supplement | Aug 13, 2025 | FDA |
Fluency Plus Endovascular Stent GraftP130029/S015 | Bard Peripheral Vascular, Inc. | PMA supplement | Jun 22, 2026 | FDA |
Explore the linked device profile
Other records with product code PFV
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
WRAPSODY Cell-Impermeable EndoprosthesisP240023/S005 | Merit Medical Systems, Inc. | PMA supplement | Jun 11, 2026 | FDA |
Covera Vascular Covered StentP170042/S015 | C.R. Bard, Inc. | PMA supplement | Jun 10, 2026 | FDA |
| W. L. Gore & Associates, Inc. | PMA supplement | May 26, 2026 | FDA | |
Covera Vascular Covered StentP170042/S014 | C.R. Bard, Inc. | PMA supplement | Dec 16, 2025 | FDA |
WRAPSODY Cell-Impermeable EndoprosthesisP240023/S004 | Merit Medical Systems, Inc. | PMA supplement | Dec 11, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Bard Peripheral Vascular, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1415 W. 3rd St., Tempe, AZ, 85281
Sources and methodology
- Original FDA record: P130029/S014
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



